The Effectiveness of Pneumococcal Conjugate Vaccines
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: 30 November 2024 | Viewed by 390
Special Issue Editor
2. Servicio de Microbiologia, Hospital Universitario Donostia, Paseo Dr Beguiristain s/n, 20014 San Sebastian, Spain
Interests: respiratory infections; pneumococcal pneumonia; pneumococcal vaccines; lung microbiome
Special Issue Information
Dear Colleagues,
Pneumococcal disease is a vaccine-preventable illness that causes a significant amount of mortality worldwide, particularly among children aged under five years old. The use of pneumococcal conjugate vaccines has led to a shift in the epidemiology of invasive and non-invasive pneumococcal diseases in regions where they have been implemented. In those who have been vaccinated, there has been a decrease in infections caused by vaccine serotypes, and the lower carriage of these serotypes has led to herd protection benefits for those who have not been vaccinated; however, the positive effects of conjugate vaccines have been undermined by the emergence and spread of non-vaccine serotypes, which threaten the efficacy of currently available vaccines. Many studies have been conducted globally to examine the effectiveness of pneumococcal conjugate vaccines; however, ongoing research is still necessary to ensure the proper surveillance of pneumococcal disease until universal pneumococcal vaccines are developed.
We invite contributions of original reports, observations, or reviews on the following topics:
- Pneumococcal disease and vaccines.
- Vaccination and epidemiology.
- Current vaccines and emerging serotypes.
- Baseline studies of the PCV13 serotype before the implementation of higher-valent conjugate vaccines.
Dr. Jose María Marimón
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pneumococcal conjugate vaccines
- pneumococcal diseases
- streptococcus pneumoniae serotypes
- serotype replacement
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
